Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 18/20 | 0.64 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26621783 | 1.00 | DRD4 (0.64) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL16932256 | 0.92 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL26136158 | 0.92 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL30194850 | 0.92 | DRD4 (0.56) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL9056881 | 0.89 | DRD4 (0.53) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL9581802 | 0.88 | DRD4 (0.66) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL26621776 | 0.86 | DRD4 (0.52) | DRD4DRD2DRD3 | |
| SCHEMBL26621711 | 0.85 | DRD4 (0.63) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL9582052 | 0.84 | DRD4 (0.73) | DRD4DRD2DRD3CYP1A2CYP3A4 | |
| SCHEMBL9582407 | 0.84 | DRD4 (0.73) | DRD4DRD2DRD3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008121685-A1 | METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| EP-1948188-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | DRD4 4782/4885DRD2 4771/4885DRD3 4756/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | DRD4 4782/4885DRD2 4771/4885DRD3 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.